MentionFox
Home › Executive changes › InMed Pharmaceuticals Inc.
Leadership changes · INM · SEC Form 8-K, Item 5.02

Leadership changes at InMed Pharmaceuticals Inc. (2026)

Before you join, sell to or invest in InMed Pharmaceuticals Inc.

MentionFox check on InMed Pharmaceuticals Inc.: only 2 sources on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/inmed-pharmaceuticals

  • Note: Layoff plan disclosed Mar 2026 (filing)

Check InMed Pharmaceuticals Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about InMed Pharmaceuticals Inc.?

Who joined and who left InMed Pharmaceuticals Inc. (INM)? 2 appointments reported on 2026-11-10, each cited to the company's own filing.

Gregory Divis was named President and Chief Executive Officer of InMed Pharmaceuticals Inc. As of November 14, 2026, InMed Pharmaceuticals Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on November 10, 2026, naming 2 appointments (Form 8-K, November 10, 2026).

InMed Pharmaceuticals Inc. named a new President and Chief Executive Officer on Nov 10. 29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Fairmount Funds Management LLC also filed stake reports on 14 other companies ↓

Sell to companies like InMed Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes2
In (appointed)2
Latest filing2026-11-10

InMed Pharmaceuticals Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-11-10. It names 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as InMed Pharmaceuticals Inc. files it.

Layoffs on record: 1 filing or notice, latest 2026-03-06 (layoff filings and notices).

Also on the record for InMed Pharmaceuticals Inc.

DateRecordFigureOur pageSource
November 13, 2026Stake report, Schedule 13G, by Commodore Capital LP5.6% of the class5%+ stakesSource
November 13, 2026Stake report, Schedule 13G, by Deep Track Capital, LP5.64% of the class5%+ stakesSource
November 12, 2026Stake report, Schedule 13D, by Fairmount Funds Management LLC19.99% of the class5%+ stakesSource
November 6, 2026Acquired Mentari$490MAcquisitionSource
October 7, 2026Stake report, Schedule 13G/A, by ADAR1 Capital Management, LLC17.2% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G, by Ikarian Capital, LLC4.2% of the class5%+ stakesSource
June 10, 2026Stake report, Schedule 13D, by Vivo Opportunity Fund Holdings, L.P.21.7% of the class5%+ stakesSource
June 5, 2026Stake report, Schedule 13G, by ADAR1 Capital Management, LLC24.1% of the class5%+ stakesSource
May 27, 2026Stake report, Schedule 13G, by Squadron Master Fund LP9.8% of the class5%+ stakesSource
January 20, 2026Stake report, Schedule 13G, by SABBY MANAGEMENT, LLC9.9% of the class5%+ stakesSource

Selling to them or working with them? See who runs InMed Pharmaceuticals Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on InMed Pharmaceuticals Inc. and the records around it.

InMed Pharmaceuticals Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on InMed Pharmaceuticals Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on InMed Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on InMed Pharmaceuticals Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    11 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-11-10InPresident and Chief Executive Officer8-K, 2026-11-10
2026-11-10In8-K, 2026-11-10

Who leads InMed Pharmaceuticals Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to InMed Pharmaceuticals Inc.?

New leaders reset buying decisions — get the Full Report on InMed Pharmaceuticals Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch InMed Pharmaceuticals Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the President and Chief Executive Officer at InMed Pharmaceuticals Inc., with the record behind each one.

Find candidates like President and Chief Executive Officer at InMed Pharmaceuticals Inc.

Every change, in the filing's words

Filed 2026-11-10 · 8-K

Appointed: Gregory Divis, President and Chief Executive Officer

On November 6, 2026, the Company's board of directors appointed Gregory Divis as the Company's President and Chief Executive Officer, Brett Hagen as the Company's Senior Vice President, Finance and Chief Accounting Officer, and Jerad Seurer as the Company's General Counsel and Corporate Secretary, each to serve at the discretion of the Board.

Appointed: Brett Hagen

Mr. Hagen will serve as the Company's principal financial officer and principal accounting officer.

Also stated in this filing

  • Departure of Directors and Certain Officers On November 6, 2026, Eric A. Adams, John Bathery, Andrew Hull, Neil Klompas and Nicole Lemerond resigned from the Company's board of directors and its committees on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company's operations, policies or practices.
  • In addition, on November 6, 2026, Eric A. Adams, InMed's President and Chief Executive Officer, Neeta Jagpal, InMed's Chief Financial Officer and Corporate Secretary, Michael Woudenberg, InMed's Chief Operating Officer, and Eric Hsu, InMed's Senior Vice President, Preclinical Research & Development, each resigned as an executive officer of the Company at the Closing.
  • The departures of Mr. Adams, Ms. Jagpal, Mr. Woudenberg and Dr. Hsu were not the result of any disagreement with InMed relating to InMed's operations, policies or practices.
  • Stock Incentive Plan On September 29, 2026, InMed's board of directors approved the Mentari Therapeutics, Inc. 2026 Stock Incentive Plan (the "2026 Stock Plan"), subject to shareholder approval and the consummation of the Merger.
  • On November 4, 2026, InMed's shareholders approved the 2026 Stock Plan at the InMed Shareholders Meeting.

Tools for this story

Each opens in a new tab, filled in for InMed Pharmaceuticals Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/inmed-pharmaceuticals
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
InMed Pharmaceuticals Inc. names Gregory Divis CEO (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/inmed-pharmaceuticals